Evidence map›Paper›PMID 41145787›Full record

ArticleScientific reports2025

Development and validation of predictive model for emesis in cervical cancer patients receiving concurrent chemoradiotherapy based on multi-institutional retrospective study.

Kensuke Yoshida, Hajime Morita, Masaki Nakai, Yusuke Kawamura, Takuma Matsumoto, Yoshinobu Gohara, Naoto Hoshino, Naoya Tonomura, Manami Banba, Ayako Yamaguchi and 16 more

Abstract readMulticenter StudyValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Kensuke YoshidaDepartment of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 1432-1192-0392, Japan. yoshida@toyaku.ac.jp.
Hajime MoritaDivision of Pharmacy, St. Marianna University Hospital, Kawasaki, Japan.
Masaki NakaiDivision of Pharmacy, Ehime University Hospital, Ehime, Toon, Japan.
Yusuke KawamuraDivision of Hospital Pharmacy, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
Takuma MatsumotoDivision of Hospital Pharmacy, NHO Shikoku Cancer Center, Ehime, Matsuyama, Japan.
Yoshinobu GoharaDepartment of Pharmacy, Saga University Hospital, Saga, Japan.
Naoto HoshinoDivision of Hospital Pharmacy, Niigata University Medical and Dental Hospital, Niigata, Japan.
Naoya TonomuraDivision of Hospital Pharmacy, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan.
Manami BanbaDivision of Hospital Pharmacy, Aomori Prefectural Central Hospital, Aomori, Japan.
Ayako YamaguchiDepartment of Pharmacy, Yamagata University Hospital, Yamagata, Japan.
Masaki TachibanaDivision of Pharmacy, Nagaoka Red Cross Hospital, Nagaoka, Japan.
Tomoki FukushimaDepartment of Pharmacy, University of Yamanashi Hospital, Chuo, Japan.
Hiroki HosokawaDivision of Hospital Pharmacy, Nagaoka Chuo General Hospital, Nagaoka, Japan.
Takuya MuraDivision of Hospital Pharmacy, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan.
Tsuyoshi YabukiDivision of Pharmacy, Uonuma Kikan Hospital, Minamiuonuma, Japan.
Kyongsun PakDivision of Biostatistics, Center for Clinical Research, National Center for Child Health and Development, Setagaya, Japan.
Shinichi WatanabeDepartment of Clinical Pharmacy, College of Pharmaceutical Sciences, Matsuyama University, Matsuyama, Japan.
Anna KiyomiDepartment of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 1432-1192-0392, Japan.
Noriaki HidakaDivision of Pharmacy, Ehime University Hospital, Ehime, Toon, Japan.
Chie SaitoDivision of Hospital Pharmacy, Niigata University Medical and Dental Hospital, Niigata, Japan.
Takahiro KobayashiDivision of Pharmacy, St. Marianna University Hospital, Kawasaki, Japan.
Tomokazu ShojiDepartment of Pharmacy, University of Yamanashi Hospital, Chuo, Japan.
Motoko KanekoDepartment of Pharmacy, Yamagata University Hospital, Yamagata, Japan.
Masayoshi KogaDivision of Hospital Pharmacy, Niigata University Medical and Dental Hospital, Niigata, Japan.
Tomoya NozakiDivision of Pharmacy, St. Marianna University Hospital, Kawasaki, Japan.
Munetoshi SugiuraDepartment of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, 1432-1192-0392, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy-induced nausea and vomiting (CINV) remains a significant barrier to treatment adherence and quality of life in cervical cancer patients receiving chemoradiotherapy. No validated predictive models exist to assess CINV risk in this population. We aimed to develop and temporal validate a predictive model for CINV incidence in cervical cancer patients receiving concurrent chemoradiotherapy (CCRT). This multi-institutional, retrospective cohort study analyzed 921 patients who received CCRT with weekly cisplatin (40 mg/m

Indexed as

ChemoradiotherapyNauseaUterine Cervical NeoplasmsVomitingAdultAgedAntineoplastic AgentsCisplatinFemaleHumansMiddle AgedRetrospective StudiesROC CurveAntineoplastic AgentsCisplatinChemoradiotherapyChemotherapy-induced nausea and vomitingMulti-institutionalPredictive modelRetrospective cohort study

Identifiers

PMID41145787
PMCPMC12559208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.